Phio Pharmaceuticals Corp. (PHIO) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Phio Pharmaceuticals Corp. (PHIO) Healthcare & Pipeline Overview

Phio Pharmaceuticals Corp. is a biotechnology firm specializing in immuno-oncology therapeutics, leveraging its INTASYL platform to develop ACT therapies. The company targets tumor and immune cells by modulating gene expression, positioning itself within the competitive landscape of cancer immunotherapy.

What Is the Investment Thesis for PHIO?

Phio Pharmaceuticals Corp. presents a high-risk, high-reward investment opportunity within the immuno-oncology space. The company's INTASYL platform offers a novel approach to enhancing ACT therapies, potentially improving patient outcomes in cancer treatment. A key value driver is the successful clinical development and commercialization of its lead candidates, PH-762, PH-894, and PH-804. The collaboration with AgonOx Inc. could accelerate clinical trials and validation of Phio's technology. However, the company's small size and limited resources pose significant challenges. The success of Phio hinges on positive clinical trial results and securing additional funding to advance its pipeline. Investors should closely monitor clinical trial data and partnership developments to assess the company's progress.

Based on FMP financials and quantitative analysis

PHIO Key Highlights

Phio Pharmaceuticals focuses on immuno-oncology therapeutics, a rapidly growing area within biotechnology.

• The INTASYL platform targets tumor and immune cells by regulating genes of the immune system.
• Key drug candidates include PH-762, PH-894, and PH-804, all designed to enhance adoptive cell transfer (ACT) therapies.
• Collaboration with AgonOx Inc. supports the clinical development of novel T cell-based cancer immunotherapies.
• The company operates with a small team of 5 employees, indicating a lean operational structure.

Who Are PHIO's Competitors?

PHIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHIO's Key Strengths?

Proprietary INTASYL platform offers a novel approach to immuno-oncology.

• Focus on adoptive cell transfer (ACT) therapies, a promising area in cancer treatment.
• Collaboration with AgonOx Inc. provides access to additional expertise and resources.
• Pipeline of drug candidates targeting key immune checkpoints and epigenetic regulators.

What Are PHIO's Weaknesses?

Small company size with limited financial resources.

• Early-stage clinical development with significant regulatory and commercialization risks.
• High dependence on the success of its lead drug candidates.
• Limited market presence and brand recognition.

What Could Drive PHIO Stock Higher?

Clinical trial results for PH-762 in adoptive cell transfer (ACT) therapies expected Q4 2026.

• Collaboration with AgonOx Inc. advancing novel T cell-based cancer immunotherapies.
• Expansion of the INTASYL platform to new therapeutic targets and indications.

What Are the Key Risks for PHIO?

Financial-distress signal — its Altman Z-Score of -13.15 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-77.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays could negatively impact the company's valuation.
• Competition from larger pharmaceutical companies with established immuno-oncology products.
• Limited financial resources may hinder the company's ability to advance its pipeline.
• Regulatory hurdles and potential delays in clinical trials.

What Are the Growth Opportunities for PHIO?

• Expansion of INTASYL Platform Applications: Phio can expand the application of its INTASYL platform beyond its current pipeline. This includes exploring new therapeutic targets and indications within immuno-oncology. The market for targeted therapies is projected to reach $150 billion by 2030, offering a significant opportunity for Phio to diversify its product offerings and increase its market presence. Timeline: Ongoing.
• Strategic Partnerships and Collaborations: Forming additional strategic partnerships with larger pharmaceutical companies or research institutions can provide Phio with access to resources, expertise, and funding. Collaborations can also accelerate the clinical development and commercialization of its drug candidates. The value of biotech partnerships is expected to increase by 10% annually, making this a viable growth strategy. Timeline: Ongoing.
• Advancement of Clinical Trials: Progressing its lead drug candidates, PH-762, PH-894, and PH-804, through clinical trials is crucial for Phio's growth. Positive clinical trial results can validate the efficacy of its INTASYL platform and attract further investment. The global market for cancer clinical trials is projected to reach $25 billion by 2028, highlighting the importance of clinical development. Timeline: Ongoing.
• Geographic Expansion: Expanding its operations beyond the United States into international markets can provide Phio with access to new patient populations and revenue streams. The global immuno-oncology market is expected to reach $75 billion by 2027, with significant growth potential in Asia-Pacific and Europe. Timeline: 2027.
• Acquisition or Licensing of New Technologies: Acquiring or licensing new technologies that complement its INTASYL platform can enhance Phio's competitive position and expand its product pipeline. This includes technologies related to gene editing, drug delivery, or biomarker discovery. The market for biotechnology licensing is projected to grow by 8% annually, offering opportunities for strategic acquisitions. Timeline: 2028.

What Are PHIO's Competitive Advantages?

• Proprietary INTASYL platform for targeting tumor and immune cells.
• Pipeline of drug candidates focused on enhancing adoptive cell transfer (ACT) therapies.
• Strategic collaboration with AgonOx Inc. for clinical development.
• Intellectual property protection for its technologies and drug candidates.

What Does PHIO Do?

Phio Pharmaceuticals Corp., founded in 2011 and headquartered in Marlborough, Massachusetts, is a biotechnology company dedicated to developing innovative immuno-oncology therapeutics. The company's core technology revolves around its proprietary INTASYL platform, which focuses on targeting tumor and immune cells by regulating genes of the immune system. This platform is designed to enhance the effectiveness of adoptive cell transfer (ACT) therapies, a promising approach in cancer treatment. Phio's pipeline includes several drug candidates, such as PH-762, which aims to activate immune cells to recognize and eliminate cancer cells by reducing the expression of the checkpoint protein PD-1. Another candidate, PH-894, targets and silences the epigenetic protein BRD4, an intracellular regulator of gene expression, also for use in ACT. Additionally, PH-804 targets the suppressive immune receptor TIGIT, a checkpoint protein present on T cells and natural killer cells, with the goal of improving ACT outcomes. Formerly known as RXi Pharmaceuticals Corporation until November 2018, Phio has strategically shifted its focus to immuno-oncology. The company collaborates with AgonOx Inc. to advance the clinical development of novel T cell-based cancer immunotherapies, expanding its reach and expertise in the field. With a small team of 5 employees, Phio operates within the highly competitive biotechnology sector, striving to make a significant impact on cancer treatment through its targeted therapeutic approaches.

What Products and Services Does PHIO Offer?

• Develop immuno-oncology therapeutics.
• Utilize the INTASYL therapeutic platform to target tumor and immune cells.
• Regulate genes of the immune system to enhance cancer treatment.
• Develop PH-762 to activate immune cells and kill cancer cells by reducing PD-1 expression.
• Develop PH-894 to silence the epigenetic protein BRD4.
• Develop PH-804 to target the suppressive immune receptor TIGIT.
• Collaborate with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies.

How Does PHIO Make Money?

• Develop and commercialize immuno-oncology therapeutics.
• Generate revenue through partnerships and collaborations with pharmaceutical companies.
• Out-license its INTASYL platform and drug candidates to other companies.
• Secure funding through grants, venture capital, and public offerings.

What Industry Does PHIO Operate In?

Phio Pharmaceuticals operates within the competitive biotechnology industry, specifically focusing on immuno-oncology. The immuno-oncology market is experiencing substantial growth, driven by advancements in understanding the immune system's role in cancer and the development of novel therapies. Companies like Phio are striving to improve cancer treatment outcomes by enhancing the body's natural defenses. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying for market share in this rapidly evolving field. Success depends on innovative technologies, positive clinical trial results, and strategic partnerships.

Who Are PHIO's Key Customers?

• Pharmaceutical companies seeking to expand their immuno-oncology portfolios.
• Research institutions and hospitals conducting clinical trials.
• Patients with cancer who may benefit from Phio's therapies.
• Investors interested in the biotechnology and healthcare sectors.

Wall Street analysts project Phio Pharmaceuticals Corp. revenue of about $0 for fiscal 2026, with EPS near $-1.38.

Phio Pharmaceuticals Corp. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 13.3% above estimates on average.

Phio Pharmaceuticals Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -13.15 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Phio Pharmaceuticals Corp. stands at -77.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -62.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -83.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 66.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -85.5%, the inverse of the P/E and a quick read on earnings relative to price.

Phio Pharmaceuticals Corp. (PHIO) Valuation Context

Valued at $14.1M, PHIO is classified as a micro-cap stock. Relative to its peer group, PHIO's quantitative score of 30/100 is below the peer average of 69/100.

Company Profile

Phio Pharmaceuticals Corp. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in King of Prussia, US. The company is led by CEO Robert L. Bitterman. PHIO has traded publicly since 2012.

PHIO Financials

PHIO Latest News

No recent news available for PHIO.

PHIO Analyst Consensus

PHIO MoonshotScore

Common Questions About PHIO (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources